Friday, 16 Nov 2018

You are here

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.

In a 12 week, phase 2, double-blind trial, BMS-986165 (TYK2 inhibitor) or placebo was given to 267 patients with active moderate-to-severe psoriasis, who previously failed to respond to other targeted cytokine inhibitors.  Patients received wither 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo. The primary end point was a 75% or greater reduction from baseline in the Psoriasis Area and Severity Index (PASI75) score at week 12.

At week 12, the PASI 75 response rates were:

  • PBO: 7% (3 of 45 patients)
  • 3 mg of BMS-986165 qod;  9% (4 of 44 patients) (P=0.49 vs. placebo)
  • 3 mg qd: 39% (17 of 44 patients) (P<0.001 vs. placebo)
  • 3 mg bid:  69% (31 of 45 patients) (P<0.001 vs. placebo)
  • 6 mg bid: 67% (30 of 45 patients) (P<0.001 vs. placebo)
  • 12 mg qd: 75% (33 of 44 patients) (P<0.001 vs. placebo).

Discontinuation rates were low, generally about 2% (ranging from 2-7%) and there were 3 serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment.

Targeted inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in significant clearing of psoriasis.

(Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT02931838.)

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

Updates on Psoriatic Arthritis at ACR 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.

Axial Spondylitis Abstracts Roundup

There have been a number of interesting posters and presentations covering the field of axial spondyloarthropathy. I’ve picked out a few points that I found particularly relevant.

Classification Criteria

NK cells and a Potential Role in the Development of PsA vs PsC (Cutaneous Psoriasis)

Human NK cells express multiple receptors that interact with HLA class I molecules which, in turn, suppy peptides that bind HLA-E to form CD94/NKG2A NK receptor ligands. These peptides correspond to -22 to -14 residues in the leader sequences of HLA-A, HLA-B and HLA-C binding to the HLA-E site. Methionine – 21 delivers functional peptides in stark contrast to threonine – 21 which does not.